Literature DB >> 25361437

(-)-Epicatechin prevents alterations in the metabolism of superoxide anion and nitric oxide in the hearts of L-NAME-treated rats.

Barbara Piotrkowski1, Valeria Calabró, Mónica Galleano, César G Fraga.   

Abstract

The aim of this work was to evaluate the effects of (-)-epicatechin administration in the heart of a rat model with reduced NO production that follows a short-term treatment with L-NAME. Sprague-Dawley rats were treated for 4 d with L-NAME in the absence or presence of (-)-epicatechin in the diet. The redox status in cardiac tissue was improved by (-)-epicatechin administration. L-NAME treatment induced a decrease in NO synthase activity (-62%, p<0.05) and an increase in NADPH-dependent superoxide anion production (+300%, p<0.05) that were totally prevented by (-)-epicatechin administration. These effects of (-)-epicatechin were associated with a higher endothelial NO synthase phosphorylation at an activation site and a reduced expression of the regulatory subunit, p47(phox), suggesting the involvement of posttranslational mechanisms in (-)-epicatechin action. Thus, the (-)-epicatechin treatment would restore NO steady state levels in vivo through effects on both, its synthesis and degradation via the reaction with superoxide anion. The fact that (-)-epicatechin is commonly present in human diet makes this compound a reasonable explanation for the positive cardiovascular effects of a high consumption of fruits and vegetables.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25361437     DOI: 10.1039/c4fo00554f

Source DB:  PubMed          Journal:  Food Funct        ISSN: 2042-6496            Impact factor:   5.396


  6 in total

Review 1.  ( -)-Epicatechin and cardiometabolic risk factors: a focus on potential mechanisms of action.

Authors:  Ezequiel J Hid; Juana I Mosele; Paula D Prince; Cesar G Fraga; Monica Galleano
Journal:  Pflugers Arch       Date:  2021-11-23       Impact factor: 3.657

2.  Epicatechin's cardiovascular protective effects are mediated via opioid receptors and nitric oxide.

Authors:  Kirsty MacRae; Kylie Connolly; Rebecca Vella; Andrew Fenning
Journal:  Eur J Nutr       Date:  2018-05-10       Impact factor: 5.614

3.  (-)-Epicatechin Prevents Blood Pressure Increase and Reduces Locomotor Hyperactivity in Young Spontaneously Hypertensive Rats.

Authors:  M Kluknavsky; P Balis; A Puzserova; J Radosinska; A Berenyiova; M Drobna; S Lukac; J Muchova; I Bernatova
Journal:  Oxid Med Cell Longev       Date:  2016-11-03       Impact factor: 6.543

4.  LC-MS analysis of Myrica rubra extract and its hypotensive effects via the inhibition of GLUT 1 and activation of the NO/Akt/eNOS signaling pathway.

Authors:  Jing Li; Huiling Wang; Jian Li; Yonggang Liu; Hong Ding
Journal:  RSC Adv       Date:  2020-02-04       Impact factor: 4.036

5.  (-)-Epicatechin Reduces the Blood Pressure of Young Borderline Hypertensive Rats During the Post-Treatment Period.

Authors:  Michal Kluknavsky; Peter Balis; Martin Skratek; Jan Manka; Iveta Bernatova
Journal:  Antioxidants (Basel)       Date:  2020-01-23

Review 6.  Mechanisms Modified by (-)-Epicatechin and Taxifolin Relevant for the Treatment of Hypertension and Viral Infection: Knowledge from Preclinical Studies.

Authors:  Iveta Bernatova; Silvia Liskova
Journal:  Antioxidants (Basel)       Date:  2021-03-16
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.